On the stock market since 2004, it operates in the world of health and science. It has 13 employees. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
An average decline of 20% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
Executive selling isn’t always bad news; people sell for personal reasons too. Still, the thin buying side is worth noting.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Cost Efficiency: As sales grow, profit fails to keep the same pace.
An investor who bought at the very peak is down 98% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $13.1M in the vault; even if every debt were paid off, $13.0M would remain.
A loss of $7.8M against $3.0M in annual sales. And on top of that, sales fell from the year before.
At the current pace of spending, the cash lasts about 1.7 years. After that, the company needs to find new money.
On our five-subject report card, NURO sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: NURO is a small company that closed last year at a loss. The road back to profit runs through spending discipline.